Short-term, high-dose hydroxychloroquine corneal toxicity.

ABSTRACT:

Purpose

To describe the corneal findings and management of a 61-year-old female with vortex keratopathy following short term, high dose hydroxychloroquine used in the setting of a clinical trial for recurrent breast cancer.

Observations

The patient was found to have significant corneal vortex keratopathy without retinal pathology within 3 months of 1200 mg daily hydroxychloroquine treatment as an adjuvant medication for cancer therapy. Cessation of the medication led to the resolution of the corneal verticillata within 1 month yet the vision did not return to baseline. Ultimately, remaining irregular astigmatism and ocular surface disease required a scleral contact lens to achieve a BSCVA of 20/25 OU.

Conclusions and importance

Hydroxychloroquine-induced vortex kerato

SUBMITTER: Savage DE 

PROVIDER: S-EPMC7180161 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature